Cargando…

Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection

In vaccinees who were infected with SARS-CoV in 2003, we observed greater antibody responses against spike and nucleoprotein of both SARS-CoV-2 and SARS-CoV after a single dosage of inactivated SARS-CoV-2 vaccine. After receiving the second vaccination, antibodies against RBD of SARS-CoV-2 Wuhan, Be...

Descripción completa

Detalles Bibliográficos
Autores principales: Liang, Huang, Zheng, Peiyan, Wang, Qian, Deng, Yijun, Liang, Dan, Yi, Haisu, Cheng, Yuanyi, Zhao, Xinwei, Ma, Jing, Yang, Yidong, Hu, Peiyu, Zheng, Pingqian, Zhang, Yudi, Huang, Shuangshuang, Lin, Xiancheng, Ke, Changwen, Niu, Xuefeng, Sun, Baoqing, Chen, Ling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176697/
https://www.ncbi.nlm.nih.gov/pubmed/35615992
http://dx.doi.org/10.1080/22221751.2022.2076613
_version_ 1784722722893332480
author Liang, Huang
Zheng, Peiyan
Wang, Qian
Deng, Yijun
Liang, Dan
Yi, Haisu
Cheng, Yuanyi
Zhao, Xinwei
Ma, Jing
Yang, Yidong
Hu, Peiyu
Zheng, Pingqian
Zhang, Yudi
Huang, Shuangshuang
Lin, Xiancheng
Ke, Changwen
Niu, Xuefeng
Sun, Baoqing
Chen, Ling
author_facet Liang, Huang
Zheng, Peiyan
Wang, Qian
Deng, Yijun
Liang, Dan
Yi, Haisu
Cheng, Yuanyi
Zhao, Xinwei
Ma, Jing
Yang, Yidong
Hu, Peiyu
Zheng, Pingqian
Zhang, Yudi
Huang, Shuangshuang
Lin, Xiancheng
Ke, Changwen
Niu, Xuefeng
Sun, Baoqing
Chen, Ling
author_sort Liang, Huang
collection PubMed
description In vaccinees who were infected with SARS-CoV in 2003, we observed greater antibody responses against spike and nucleoprotein of both SARS-CoV-2 and SARS-CoV after a single dosage of inactivated SARS-CoV-2 vaccine. After receiving the second vaccination, antibodies against RBD of SARS-CoV-2 Wuhan, Beta, Delta, and recently emerged Omicron are significantly higher in SARS-CoV experienced vaccinees than in SARS-CoV naïve vaccinees. Neutralizing activities measured by authentic viruses and pseudoviruses of SARS-CoV, SARS-CoV-2 Wuhan, Beta, and Delta are greater in SARS-CoV experienced vaccinees. In contrast, only weak neutralizing activities against SARS-CoV-2 and variants were detected in SARS-CoV naïve vaccinees. By 6 months after the second vaccination, neutralizing activities were maintained at a relatively higher level in SARS-CoV experienced vaccinees but were undetectable in SARS-CoV naïve vaccinees. These findings suggested a great possibility of developing a universal vaccine by heterologous vaccination using spike antigens from different SARS-related coronaviruses.
format Online
Article
Text
id pubmed-9176697
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91766972022-06-09 Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection Liang, Huang Zheng, Peiyan Wang, Qian Deng, Yijun Liang, Dan Yi, Haisu Cheng, Yuanyi Zhao, Xinwei Ma, Jing Yang, Yidong Hu, Peiyu Zheng, Pingqian Zhang, Yudi Huang, Shuangshuang Lin, Xiancheng Ke, Changwen Niu, Xuefeng Sun, Baoqing Chen, Ling Emerg Microbes Infect Coronaviruses In vaccinees who were infected with SARS-CoV in 2003, we observed greater antibody responses against spike and nucleoprotein of both SARS-CoV-2 and SARS-CoV after a single dosage of inactivated SARS-CoV-2 vaccine. After receiving the second vaccination, antibodies against RBD of SARS-CoV-2 Wuhan, Beta, Delta, and recently emerged Omicron are significantly higher in SARS-CoV experienced vaccinees than in SARS-CoV naïve vaccinees. Neutralizing activities measured by authentic viruses and pseudoviruses of SARS-CoV, SARS-CoV-2 Wuhan, Beta, and Delta are greater in SARS-CoV experienced vaccinees. In contrast, only weak neutralizing activities against SARS-CoV-2 and variants were detected in SARS-CoV naïve vaccinees. By 6 months after the second vaccination, neutralizing activities were maintained at a relatively higher level in SARS-CoV experienced vaccinees but were undetectable in SARS-CoV naïve vaccinees. These findings suggested a great possibility of developing a universal vaccine by heterologous vaccination using spike antigens from different SARS-related coronaviruses. Taylor & Francis 2022-06-02 /pmc/articles/PMC9176697/ /pubmed/35615992 http://dx.doi.org/10.1080/22221751.2022.2076613 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group, on behalf of Shanghai Shangyixun Cultural Communication Co., Ltd https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Coronaviruses
Liang, Huang
Zheng, Peiyan
Wang, Qian
Deng, Yijun
Liang, Dan
Yi, Haisu
Cheng, Yuanyi
Zhao, Xinwei
Ma, Jing
Yang, Yidong
Hu, Peiyu
Zheng, Pingqian
Zhang, Yudi
Huang, Shuangshuang
Lin, Xiancheng
Ke, Changwen
Niu, Xuefeng
Sun, Baoqing
Chen, Ling
Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
title Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
title_full Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
title_fullStr Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
title_full_unstemmed Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
title_short Broad and durable antibody response after vaccination with inactivated SARS-CoV-2 in individuals with a history of 2003 SARS-CoV infection
title_sort broad and durable antibody response after vaccination with inactivated sars-cov-2 in individuals with a history of 2003 sars-cov infection
topic Coronaviruses
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176697/
https://www.ncbi.nlm.nih.gov/pubmed/35615992
http://dx.doi.org/10.1080/22221751.2022.2076613
work_keys_str_mv AT lianghuang broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT zhengpeiyan broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT wangqian broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT dengyijun broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT liangdan broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT yihaisu broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT chengyuanyi broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT zhaoxinwei broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT majing broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT yangyidong broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT hupeiyu broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT zhengpingqian broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT zhangyudi broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT huangshuangshuang broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT linxiancheng broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT kechangwen broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT niuxuefeng broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT sunbaoqing broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection
AT chenling broadanddurableantibodyresponseaftervaccinationwithinactivatedsarscov2inindividualswithahistoryof2003sarscovinfection